Douglas Treco compensation by year
Inozyme Pharma Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $375,000 | $541,667 |
| Bonus | $7,500 | $0 |
| Stock awards | $573,000 | $0 |
| Option awards | $4,134,601 | $1,933,375 |
| Non-equity incentive | $200,000 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $9,375 | $10,350 |
| Total | $5,299,476 | $2,485,392 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Inozyme Pharma, Inc. DEF 14A filed April 29, 2025, accession 0000950170-25-060198, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Inozyme Pharma, Inc. filed document, accession 0000950170-25-060198. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 75,000 | $207,750 | — |
| Option | 243,750 | — | $5.77 |
| Option | 466,667 | — | $5.73 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Inozyme Pharma, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2024 proxy (filed April 29, 2025)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-07-01 | Disposition to the issuer derivative | — | 150,000 | — | 0 |
| 2025-07-01 | Disposition to the issuer derivative | — | 86,979 | — | 0 |
| 2025-07-01 | U | — | 43,861 | $4.00 | 0 |
| 2025-07-01 | Disposition to the issuer derivative | — | 400,000 | — | 0 |
| 2025-06-25 | Grant or award | — | 2,815 | $0.74 | 43,861 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Inozyme Pharma’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Douglas Treco · this page | Chief Executive Officer and Chairman | $2,485,392 |
| Matthew Winton | Senior Vice President and Chief Operating Officer | $1,764,899 |
| Sanjay Subramanian | Senior Vice President and Chief Financial Officer and Head of Business Development | $1,703,737 |
Board service
Inozyme Pharma board · FY2024How this board is paid
Company policy: Inozyme Pharma pays directors a $40,000 cash retainer and $123,200 in Options. As stated in Inozyme Pharma's FY2024 proxy.
Committees
Research and Development
The full Inozyme Pharma compensation record
free company briefThis page is one person within Inozyme Pharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Inozyme Pharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Inozyme Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order INZY
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.